Summary & Overview
HCPCS Level II Q5119: Injection, rituximab-pvvr (Ruxience), 10 mg
HCPCS Level II code Q5119 designates the 10 mg unit for injection of rituximab-pvvr, a biosimilar sold as Ruxience. As a product-level HCPCS code for a biologic biosimilar, Q5119 matters nationally for facility and professional billing, inventory management, and payer coverage determinations for conditions treated with rituximab-class therapies. The code supports accurate drug reporting for infusion services and impacts reimbursement and utilization monitoring across settings that administer parenteral oncology and immunology agents.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for rituximab biosimilars, common sites of service for administration, and the payer landscape that commonly applies to biologic infusions. The publication also covers typical billing considerations for HCPCS-level biologic units, benchmark measures used by major payers, and recent policy updates that affect coverage and coding for biosimilars. Where input data is not provided, the report notes that information is not available in the input.
Billing Code Overview
HCPCS Level II code Q5119 represents injection of rituximab-pvvr, a biosimilar marketed as Ruxience, dosed in 10 mg units. This code is used to bill for administration of the biosimilar product formulation when supplied in the specified unit quantity.
-
Service type: Parenteral therapeutic drug administration
-
Typical site of service: Infusion center, hospital outpatient department, or physician office where intravenous or subcutaneous biologic therapies are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a B-cell mediated hematologic or autoimmune condition such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, or a severe autoimmune cytopenia who is scheduled to receive intravenous biosimilar rituximab (Q5119, ruxience) as part of induction, maintenance, or rescue therapy. The patient arrives at an outpatient infusion center or hospital outpatient infusion clinic where nursing triage verifies diagnosis, weight, laboratory tests (including CBC and chemistries), and premedications (acetaminophen, antihistamine, corticosteroid) per protocol. A licensed clinician (oncologist, hematologist, or rheumatologist) documents the treatment plan and orders the rituximab dose in milligrams; pharmacy prepares the appropriate vial(s) of Q5119 (10 mg incremental billing units) and labels the infusion bag. The patient is consented for infusion-related risks; baseline vital signs are recorded. The infusion nurse establishes IV access, administers premedications, initiates the infusion at a protocol-defined rate with careful monitoring for infusion reactions, and documents administration, lot number, and amount billed using Q5119 units. Post-infusion monitoring is performed; any acute adverse events are managed per protocol. Billing captures the drug J3-equivalent HCPCS code Q5119 for the product, associated drug administration CPT codes for infusion time, and any applicable modifiers reflecting payer-specific circumstances such as professional component, reconstitution, partial administration, or billing by a qualifying alternative payer arrangement.
Coding Specifications
| Modifier |
|---|